skip to content
  1. Home
  2. >
  3. Questions
  4. >
  5. GUD: Would appreciate your comments on the recent quarterly report. [Knight Therapeutics Inc.]
You can view 1 more answer this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Would appreciate your comments on the recent quarterly report. Do you see any basis for the stock price to start increasing?
Asked by Sig on November 07, 2024
5i Research Answer:

EPS of 1c missed estimates of 2.3c; revenue of $92.2M beat estimates of $89.0M. EBITDA of $13.5M missed estmates by 5%. Revenue rose 13%. EBITDA fell 5.7%. Guidance for revenue of $355M was affirmed. One broker (Mackie) cut its rating today. While hardly a disaster, the stock has taken a hit today as it is just a continuing story of 'not much going on here'. Investors remain impatient while everything else is going up.